Peptide Therapeutics Market (Application: Metabolic, Oncology, Gastrointestinal, Cardiovascular, Neurological, and Others; and Route of Administration: Parenteral, Oral, and Others) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20

Peptide Therapeutics Market (Application: Metabolic, Oncology, Gastrointestinal, Cardiovascular, Neurological, and Others; and Route of Administration: Parenteral, Oral, and Others) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031


Peptide Therapeutics Market – Scope of Report

TMR’s report on the global peptide therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global peptide therapeutics market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global peptide therapeutics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the peptide therapeutics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global peptide therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global peptide therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global peptide therapeutics market.

The report delves into the competitive landscape of the global peptide therapeutics market. Key players operating in the global peptide therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global peptide therapeutics market profiled in this report.

Key Questions Answered in Global peptide therapeutics Market Report
  • What is the sales/revenue generated by peptide therapeutics across all regions during the forecast period?
  • What are the opportunities in the global peptide therapeutics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?
Peptide Therapeutics Market – Research Objectives and Research Approach

The comprehensive report on the global peptide therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global peptide therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global peptide therapeutics market.


1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Peptide Therapeutics Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
  4.3.1. Drivers
  4.3.2. Restraints
  4.3.3. Opportunities
4.4. Global Peptide Therapeutics Market Analysis and Forecasts, 2023 - 2031
5. Key Insights
5.1. FDA-approved Peptide Therapeutics in 2022
5.2. Peptide Drugs Approved Since 2000, with their Targets and Indications
5.3. White Space Analysis
5.4. Porter's Analysis
5.5. Pipeline Analysis
5.6. Peptide Drugs Chemical Structure Trend Analysis
5.7. Separation Media Used for Peptide Drugs
5.8. COVID-19 Impact Analysis
6. Global Peptide Therapeutics Market Analysis and Forecasts, By Product Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Product Type, 2023 - 2031
  6.3.1. Innovative
  6.3.2. Generic
6.4. Market Attractiveness By Product Type
7. Global Peptide Therapeutics Market Analysis and Forecasts, By Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Application, 2023 - 2031
  7.3.1. Metabolic
  7.3.2. Oncology
  7.3.3. Gastrointestinal
  7.3.4. Cardiovascular
  7.3.5. Neurological
  7.3.6. Others
7.4. Market Attractiveness By Application
8. Global Peptide Therapeutics Market Analysis and Forecasts, By Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Route of Administration, 2023 - 2031
  8.3.1. Parenteral
  8.3.2. Oral
  8.3.3. Others
8.4. Market Attractiveness By Route of Administration
9. Global Peptide Therapeutics Market Analysis and Forecasts, By Types of Peptide
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast By Types of Peptide, 2023 - 2031
  9.3.1. Native Peptides
  9.3.2. Analog Peptides
  9.3.3. Heterologous Peptides
9.4. Market Attractiveness By Types of Peptide
10. Global Peptide Therapeutics Market Analysis and Forecasts, By Technology
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast By Technology, 2023 - 2031
  10.3.1. Liquid Phase
  10.3.2. Solid Phase
  10.3.3. Hybrid
10.4. Market Attractiveness By Technology
11. Global Peptide Therapeutics Market Analysis and Forecasts, By Manufacturing Type
11.1. Introduction & Definition
11.2. Key Findings / Developments
11.3. Market Value Forecast By Manufacturing Type,2023 - 2031
  11.3.1. In-house
  11.3.2. CMO
11.4. Market Attractiveness By Manufacturing Type
12. Global Peptide Therapeutics Market Analysis and Forecasts, By Region
12.1. Key Findings
12.2. Market Value Forecast By Region
  12.2.1. North America
  12.2.2. Europe
  12.2.3. Asia Pacific
  12.2.4. Latin America
  12.2.5. Middle East & Africa
12.3. Market Attractiveness By Country/Region
13. North America Peptide Therapeutics Market Analysis and Forecast
13.1. Introduction
  13.1.1. Key Findings
13.2. Market Value Forecast By Product Type,2023 - 2031
  13.2.1. Innovative
  13.2.2. Generic
13.3. Market Value Forecast By Application,2023 - 2031
  13.3.1. Metabolic
  13.3.2. Oncology
  13.3.3. Gastrointestinal
  13.3.4. Cardiovascular
  13.3.5. Neurological
  13.3.6. Others
13.4. Market Value Forecast By Route of Administration,2023 - 2031
  13.4.1. Parenteral
  13.4.2. Oral
  13.4.3. Others
13.5. Market Value Forecast By Types of Peptide,2023 - 2031
  13.5.1. Native Peptides
  13.5.2. Analog Peptides
  13.5.3. Heterologous Peptides
13.6. Market Value Forecast By Technology,2023 - 2031
  13.6.1. Liquid Phase
  13.6.2. Solid Phase
  13.6.3. Hybrid
13.7. Market Value Forecast By Manufacturing Type,2023 - 2031
  13.7.1. In-house
  13.7.2. CMO
13.8. Market Value Forecast By Country,2023 - 2031
  13.8.1. U.S.
  13.8.2. Canada
13.9. Market Attractiveness Analysis
  13.9.1. By Product Type
  13.9.2. By Application
  13.9.3. By Route of Administration
  13.9.4. By Types of Peptide
  13.9.5. By Technology
  13.9.6. By Manufacturing Type
  13.9.7. By Country
14. Europe Peptide Therapeutics Market Analysis and Forecast
14.1. Introduction
  14.1.1. Key Findings
14.2. Market Value Forecast By Product Type,2023 - 2031
  14.2.1. Innovative
  14.2.2. Generic
14.3. Market Value Forecast By Application,2023 - 2031
  14.3.1. Metabolic
  14.3.2. Oncology
  14.3.3. Gastrointestinal
  14.3.4. Cardiovascular
  14.3.5. Neurological
  14.3.6. Others
14.4. Market Value Forecast By Route of Administration,2023 - 2031
  14.4.1. Parenteral
  14.4.2. Oral
  14.4.3. Others
14.5. Market Value Forecast By Types of Peptide,2023 - 2031
  14.5.1. Native Peptides
  14.5.2. Analog Peptides
  14.5.3. Heterologous Peptides
14.6. Market Value Forecast By Technology,2023 - 2031
  14.6.1. Liquid Phase
  14.6.2. Solid Phase
  14.6.3. Hybrid
14.7. Market Value Forecast By Manufacturing Type,2023 - 2031
  14.7.1. In-house
  14.7.2. CMO
14.8. Market Value Forecast By Country,2023 - 2031
  14.8.1. Germany
  14.8.2. U.K.
  14.8.3. France
  14.8.4. Spain
  14.8.5. Italy
  14.8.6. Rest of Europe
14.9. Market Attractiveness Analysis
  14.9.1. By Product Type
  14.9.2. By Application
  14.9.3. By Route of Administration
  14.9.4. By Types of Peptide
  14.9.5. By Technology
  14.9.6. By Manufacturing Type
  14.9.7. By Country
15. Asia Pacific Peptide Therapeutics Market Analysis and Forecast
15.1. Introduction
  15.1.1. Key Findings
15.2. Market Value Forecast By Product Type,2023 - 2031
  15.2.1. Innovative
  15.2.2. Generic
15.3. Market Value Forecast By Application,2023 - 2031
  15.3.1. Metabolic
  15.3.2. Oncology
  15.3.3. Gastrointestinal
  15.3.4. Cardiovascular
  15.3.5. Neurological
  15.3.6. Others
15.4. Market Value Forecast By Route of Administration,2023 - 2031
  15.4.1. Parenteral
  15.4.2. Oral
  15.4.3. Others
15.5. Market Value Forecast By Types of Peptide,2023 - 2031
  15.5.1. Native Peptides
  15.5.2. Analog Peptides
  15.5.3. Heterologous Peptides
15.6. Market Value Forecast By Technology,2023 - 2031
  15.6.1. Liquid Phase
  15.6.2. Solid Phase
  15.6.3. Hybrid
15.7. Market Value Forecast By Manufacturing Type,2023 - 2031
  15.7.1. In-house
  15.7.2. CMO
15.8. Market Value Forecast By Country,2023 - 2031
  15.8.1. China
  15.8.2. Japan
  15.8.3. India
  15.8.4. Australia & New Zealand
  15.8.5. Rest of Asia Pacific
15.9. Market Attractiveness Analysis
  15.9.1. By Product Type
  15.9.2. By Application
  15.9.3. By Route of Administration
  15.9.4. By Types of Peptide
  15.9.5. By Technology
  15.9.6. By Manufacturing Type
  15.9.7. By Country
16. Latin America Peptide Therapeutics Market Analysis and Forecast
16.1. Introduction
  16.1.1. Key Findings
16.2. Market Value Forecast By Product Type,2023 - 2031
  16.2.1. Innovative
  16.2.2. Generic
16.3. Market Value Forecast By Application,2023 - 2031
  16.3.1. Metabolic
  16.3.2. Oncology
  16.3.3. Gastrointestinal
  16.3.4. Cardiovascular
  16.3.5. Neurological
  16.3.6. Others
16.4. Market Value Forecast By Route of Administration,2023 - 2031
  16.4.1. Parenteral
  16.4.2. Oral
  16.4.3. Others
16.5. Market Value Forecast By Types of Peptide,2023 - 2031
  16.5.1. Native Peptides
  16.5.2. Analog Peptides
  16.5.3. Heterologous Peptides
16.6. Market Value Forecast By Technology,2023 - 2031
  16.6.1. Liquid Phase
  16.6.2. Solid Phase
  16.6.3. Hybrid
16.7. Market Value Forecast By Manufacturing Type,2023 - 2031
  16.7.1. In-house
  16.7.2. CMO
16.8. Market Value Forecast By Country,2023 - 2031
  16.8.1. Brazil
  16.8.2. Mexico
  16.8.3. Rest of Latin America
16.9. Market Attractiveness Analysis
  16.9.1. By Product Type
  16.9.2. By Application
  16.9.3. By Route of Administration
  16.9.4. By Types of Peptide
  16.9.5. By Technology
  16.9.6. By Manufacturing Type
  16.9.7. By Country
17. Middle East & Africa Peptide Therapeutics Market Analysis and Forecast
17.1. Introduction
  17.1.1. Key Findings
17.2. Market Value Forecast By Product Type,2023 - 2031
  17.2.1. Innovative
  17.2.2. Generic
17.3. Market Value Forecast By Application,2023 - 2031
  17.3.1. Metabolic
  17.3.2. Oncology
  17.3.3. Gastrointestinal
  17.3.4. Cardiovascular
  17.3.5. Neurological
  17.3.6. Others
17.4. Market Value Forecast By Route of Administration,2023 - 2031
  17.4.1. Parenteral
  17.4.2. Oral
  17.4.3. Others
17.5. Market Value Forecast By Types of Peptide,2023 - 2031
  17.5.1. Native Peptides
  17.5.2. Analog Peptides
  17.5.3. Heterologous Peptides
17.6. Market Value Forecast By Technology,2023 - 2031
  17.6.1. Liquid Phase
  17.6.2. Solid Phase
  17.6.3. Hybrid
17.7. Market Value Forecast By Manufacturing Type,2023 - 2031
  17.7.1. In-house
  17.7.2. CMO
17.8. Market Value Forecast By Country,2023 - 2031
  17.8.1. GCC Countries
  17.8.2. South Africa
  17.8.3. Rest of Middle East & Africa
17.9. Market Attractiveness Analysis
  17.9.1. By Product Type
  17.9.2. By Application
  17.9.3. By Route of Administration
  17.9.4. By Types of Peptide
  17.9.5. By Technology
  17.9.6. By Manufacturing Type
  17.9.7. By Country
18. Competition Landscape
18.1. Market Player – Competition Matrix (By Tier and Size of companies)
18.2. Market Share Analysis By Company (2022)
18.3. Company Profiles
  18.3.1. Amgen, Inc.
18.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.1.2. Product Portfolio
18.3.1.3. Financial Overview
18.3.1.4. SWOT Analysis
18.3.1.5. Strategic Overview
  18.3.2. Sachem Holding AG
18.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.2.2. Product Portfolio
18.3.2.3. Financial Overview
18.3.2.4. SWOT Analysis
18.3.2.5. Strategic Overview
  18.3.3. Eli Lilly and Company
18.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.3.2. Product Portfolio
18.3.3.3. Financial Overview
18.3.3.4. SWOT Analysis
18.3.3.5. Strategic Overview
  18.3.4. F. Hoffmann-La Roche Ltd.
18.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.4.2. Product Portfolio
18.3.4.3. Financial Overview
18.3.4.4. SWOT Analysis
18.3.4.5. Strategic Overview
  18.3.5. GlaxoSmithKline plc
18.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.5.2. Product Portfolio
18.3.5.3. Financial Overview
18.3.5.4. SWOT Analysis
18.3.5.5. Strategic Overview
  18.3.6. Novartis AG
18.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.6.2. Product Portfolio
18.3.6.3. Financial Overview
18.3.6.4. SWOT Analysis
18.3.6.5. Strategic Overview
  18.3.7. Pfizer, Inc.
18.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.7.2. Product Portfolio
18.3.7.3. Financial Overview
18.3.7.4. SWOT Analysis
18.3.7.5. Strategic Overview
  18.3.8. Sanofi
18.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.8.2. Product Portfolio
18.3.8.3. Financial Overview
18.3.8.4. SWOT Analysis
18.3.8.5. Strategic Overview
  18.3.9. Takeda Pharmaceutical Company Limited
18.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.9.2. Product Portfolio
18.3.9.3. Financial Overview
18.3.9.4. SWOT Analysis
18.3.9.5. Strategic Overview
  18.3.10. Teva Pharmaceutical Industries Ltd.
18.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.10.2. Product Portfolio
18.3.10.3. Financial Overview
18.3.10.4. SWOT Analysis
18.3.10.5. Strategic Overview

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings